157 related articles for article (PubMed ID: 32458993)
1. Similar But Not Identical: Plaque Psoriasis Exacerbation in a Patient With Crohn's Disease After Switching From CT-P13 to SB2 Infliximab Biosimilar.
Pagnini C; Di Paolo MC; De Angelis G; Torcolacci F; Milano M; Trinca D; Porciello R; Graziani MG
Inflamm Bowel Dis; 2020 Jul; 26(8):e83-e84. PubMed ID: 32458993
[No Abstract] [Full Text] [Related]
2. Implementation of CT-P13 via a Managed Switch Programme in Crohn's Disease: 12-Month Real-World Outcomes.
Plevris N; Jones GR; Jenkinson PW; Lyons M; Chuah CS; Merchant LM; Pattenden RJ; Watson EF; Ho GT; Noble CL; Din S; Shand AG; Arnott ID; Lees CW
Dig Dis Sci; 2019 Jun; 64(6):1660-1667. PubMed ID: 30535885
[TBL] [Abstract][Full Text] [Related]
3. Patients' perspectives after switching from infliximab to biosimilar CT-P13 in patients with inflammatory bowel disease: A 12-month prospective cohort study.
Petitdidier N; Tannoury J; de'Angelis N; Gagniere C; Hulin A; Rotkopf H; Mesli F; Brunetti F; Sobhani I; Amiot A
Dig Liver Dis; 2019 Dec; 51(12):1652-1660. PubMed ID: 31718934
[TBL] [Abstract][Full Text] [Related]
4. Short article: Switching to a infliximab biosimilar: short-term results of clinical monitoring in patients with inflammatory bowel disease.
Binkhorst L; Sobels A; Stuyt R; Westerman EM; West RL
Eur J Gastroenterol Hepatol; 2018 Jul; 30(7):699-703. PubMed ID: 29538037
[TBL] [Abstract][Full Text] [Related]
5. Long-Term Clinical Outcomes After Switching from Remicade
Smits LJT; Grelack A; Derikx LAAP; de Jong DJ; van Esch AAJ; Boshuizen RS; Drenth JPH; Hoentjen F
Dig Dis Sci; 2017 Nov; 62(11):3117-3122. PubMed ID: 28667429
[TBL] [Abstract][Full Text] [Related]
6. Efficacy and safety of biosimilar CT-P13 compared with originator infliximab in patients with active Crohn's disease: an international, randomised, double-blind, phase 3 non-inferiority study.
Ye BD; Pesegova M; Alexeeva O; Osipenko M; Lahat A; Dorofeyev A; Fishman S; Levchenko O; Cheon JH; Scribano ML; Mateescu RB; Lee KM; Eun CS; Lee SJ; Lee SY; Kim H; Schreiber S; Fowler H; Cheung R; Kim YH
Lancet; 2019 Apr; 393(10182):1699-1707. PubMed ID: 30929895
[TBL] [Abstract][Full Text] [Related]
7. Clinical monitoring: infliximab biosimilar CT-P13 in the treatment of Crohn's disease and ulcerative colitis.
Keil R; Wasserbauer M; Zádorová Z; Hajer J; Drastich P; Wohl P; Beneš M; Bojková M; Svoboda P; Konečný M; Falt P; Vaňásek T; Pešta M; Pešek F; Bouchner L; Koželuhová J; Novotný A; Bartůsková L; Špičák J
Scand J Gastroenterol; 2016 Sep; 51(9):1062-8. PubMed ID: 27002981
[TBL] [Abstract][Full Text] [Related]
8. Serum concentrations after switching from originator infliximab to the biosimilar CT-P13 in patients with quiescent inflammatory bowel disease (SECURE): an open-label, multicentre, phase 4 non-inferiority trial.
Strik AS; van de Vrie W; Bloemsaat-Minekus JPJ; Nurmohamed M; Bossuyt PJJ; Bodelier A; Rispens T; van Megen YJB; D'Haens GR;
Lancet Gastroenterol Hepatol; 2018 Jun; 3(6):404-412. PubMed ID: 29606564
[TBL] [Abstract][Full Text] [Related]
9. Randomized Controlled Trial: Subcutaneous vs Intravenous Infliximab CT-P13 Maintenance in Inflammatory Bowel Disease.
Schreiber S; Ben-Horin S; Leszczyszyn J; Dudkowiak R; Lahat A; Gawdis-Wojnarska B; Pukitis A; Horynski M; Farkas K; Kierkus J; Kowalski M; Lee SJ; Kim SH; Suh JH; Kim MR; Lee SG; Ye BD; Reinisch W
Gastroenterology; 2021 Jun; 160(7):2340-2353. PubMed ID: 33676969
[TBL] [Abstract][Full Text] [Related]
10. Switching from one infliximab biosimilar (CT-P13) to another infliximab biosimilar (SB2) in patients with chronic plaque psoriasis.
Gisondi P; Virga C; Piaserico S; Meneguzzo A; Odorici G; Conti A; Girolomoni G
Br J Dermatol; 2020 Aug; 183(2):397-398. PubMed ID: 32133618
[No Abstract] [Full Text] [Related]
11. Safety, efficacy, and drug survival of the infliximab biosimilar CT-P13 in post-marketing surveillance of Japanese patients with psoriasis.
Morita A; Nishikawa K; Yamada F; Yamanaka K; Nakajima H; Ohtsuki M
J Dermatol; 2022 Oct; 49(10):957-969. PubMed ID: 35799412
[TBL] [Abstract][Full Text] [Related]
12. SB2: An Infliximab Biosimilar.
Lamb YN; Scott LJ; Deeks ED
BioDrugs; 2017 Oct; 31(5):461-464. PubMed ID: 28803431
[TBL] [Abstract][Full Text] [Related]
13. Safety and efficacy of switching from infliximab biosimilar CT-P13 to infliximab biosimilar SB2 in patients with inflammatory bowel disease.
Lovero R; Losurdo G; La Fortezza RF; Terracciano F; Biscaglia G; Martino G; Nardella M; Di Leo A; Principi M; Andriulli A; Bossa F
Eur J Gastroenterol Hepatol; 2021 Feb; 32(2):201-207. PubMed ID: 33369956
[TBL] [Abstract][Full Text] [Related]
14. Real-World Safety and Efficacy of Biosimilar CT-P13 in Patients with Immune-Mediated Inflammatory Diseases: Integrated Analysis of Three Japanese Prospective Observational Studies.
Takeuchi T; Nishikawa K; Yamada F; Morita A; Ohtsuki M; Suzuki Y; Watanabe M; Yamanaka H; Hibi T
Drug Saf; 2023 Oct; 46(10):991-1005. PubMed ID: 37700154
[TBL] [Abstract][Full Text] [Related]
15. Switching from originator to biosimilar infliximab - real world data of a prospective 18 months follow-up of a single-centre IBD population.
Høivik ML; Buer LCT; Cvancarova M; Warren DJ; Bolstad N; Moum BA; Medhus AW
Scand J Gastroenterol; 2018 Jun; 53(6):692-699. PubMed ID: 29852793
[TBL] [Abstract][Full Text] [Related]
16. Serum sickness-like disease after switching to biosimilar infliximab.
Scherlinger M; Schaeverbeke T; Truchetet ME;
Rheumatology (Oxford); 2017 Nov; 56(11):2032-2034. PubMed ID: 28977481
[No Abstract] [Full Text] [Related]
17. Phosphorylation of intracellular signalling molecules in peripheral blood cells from patients with psoriasis on originator or biosimilar infliximab.
Aarebrot AK; Solberg SM; Davies R; Bader LI; Holmes TD; Gavasso S; Bryceson YT; Jonsson R; Sandvik LF; Appel S
Br J Dermatol; 2018 Aug; 179(2):371-380. PubMed ID: 29274242
[TBL] [Abstract][Full Text] [Related]
18. Biosimilar infliximab (CT-P13) in the treatment of inflammatory bowel disease: A Norwegian observational study.
Jahnsen J; Detlie TE; Vatn S; Ricanek P
Expert Rev Gastroenterol Hepatol; 2015; 9 Suppl 1():45-52. PubMed ID: 26395534
[TBL] [Abstract][Full Text] [Related]
19. Long-term efficacy and safety of CT-P13, a biosimilar of infliximab, in patients with inflammatory bowel disease: A retrospective multicenter study.
Kim NH; Lee JH; Hong SN; Yoon H; Kang HW; Lee SH; Im JP; Cha JM; Eun CS; Kim JW; Choi CH; Park DI
J Gastroenterol Hepatol; 2019 Sep; 34(9):1523-1532. PubMed ID: 30828891
[TBL] [Abstract][Full Text] [Related]
20. Effectiveness and Safety of Switching from Innovator Infliximab to Biosimilar CT-P13 in Inflammatory Rheumatic Diseases: A Real-World Case Study.
Vergara-Dangond C; Sáez Belló M; Climente Martí M; Llopis Salvia P; Alegre-Sancho JJ
Drugs R D; 2017 Sep; 17(3):481-485. PubMed ID: 28667384
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
